WITHDRAWN: LncRNA KCNQ1OT1 promotes cisplatin resistance of osteosarcoma cancer cells through the miR-335–5p/β-catenin axis

Abstract

Abstract Long noncoding RNA (lncRNA) KCNQ1OT1 (KCNQ1 opposite strand/antisense transcript 1) has been shown to participate in the tumorigenesis of several types of cancers. However, little is known about the role of KCNQ1OT1 in the chemoresistance of osteosarcoma (OS). In this study, we concentrated on the function and mechanism of KCNQ1OT1 in cisplatin resistance of OS cells. We demonstrated that KCNQ1OT1 levels were upregulated in cisplatin-resistant OS tissues and cell lines. Moreover, knockdown of KCNQ1OT1 inhibited cell proliferation, migration, and invasion and decreased cisplatin resistance in osteosarcoma 143B cells. Additionally, bioinformatics analysis and dual-luciferase reporter assays showed that miR-335-5p directly targeted KCNQ1OT1 and the 3′-UTR of β-catenin mRNA, indicating that KCNQ1OT1 regulated the expression of β-catenin via endogenous sponging of miR-335-5p. Overall, KCNQ1OT1 modulated cisplatin resistance in OS through the miR-335-5p/β-catenin axis, indicating that KCNQ1OT1 aggravates OS progression and chemoresistance to cisplatin through induction of β-catenin expression by adsorbing miR-335-5p in cisplatin-resistant OS cells, providing a theoretical basis for the treatment of chemoresistant OS.